Investigating how Mycobacterium tuberculosis uses riboflavin for growth
Riboflavin biosynthesis and utilization in Mycobacterium tuberculosis
This study is looking at how riboflavin, a type of vitamin B2, helps the tuberculosis bacteria grow and survive, with the goal of finding new ways to create vaccines that can protect people from the disease without making them sick.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project ID | NIH-11012313 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of riboflavin (vitamin B2) in the growth and survival of Mycobacterium tuberculosis, the bacteria responsible for tuberculosis. By identifying essential genes involved in riboflavin biosynthesis and uptake, the researchers aim to explore new strategies for developing vaccines that can induce protective immunity without causing disease. The study will involve testing the bacteria's ability to grow when riboflavin production is disrupted and determining if riboflavin is a limiting factor in the host environment. This approach could lead to innovative treatments and preventive measures against tuberculosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of tuberculosis infection or those with active tuberculosis.
Not a fit: Patients who are not at risk for tuberculosis or those who have already been effectively treated may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new vaccines or treatments that effectively combat tuberculosis.
How similar studies have performed: Previous research has shown promise in targeting metabolic pathways in bacteria for vaccine development, indicating that this approach could be viable.
Where this research is happening
Stony Brook, United States
- State University New York Stony Brook — Stony Brook, United States (Active)
Researchers
- Principal investigator: Seeliger, Jessica Chuang — State University New York Stony Brook
- Study coordinator: Seeliger, Jessica Chuang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.